FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Orchid Pharma's Free Cash Flow for the
three
months ended in Mar. 2026 was $0.00 Mil. Orchid Pharma's Revenue for the
three
months ended in Mar. 2026 was $25.60 Mil. Therefore, Orchid Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Orchid Pharma's FCF Margin % or its related term are showing as below:
LUX:ORCHP'
s FCF Margin % Range Over the Past 10 Years
Min: -34.81 Med: 3.01 Max: 49.25
Current: -33.55
During the past 13 years, the highest FCF Margin % of Orchid Pharma was 49.25%. The lowest was -34.81%. And the median was 3.01%.
LUX:ORCHP's FCF Margin % is ranked worse than 87.06% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.445
vs LUX:ORCHP: -33.55
Orchid Pharma FCF Margin % Related Terms
Orchid Pharma FCF Margin % Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchid Pharma (LUX:ORCHP) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Orchid Pharma and its competitors. According to the industry distribution chart, Orchid Pharma ranks #834 out of 958 companies in the Drug Manufacturers industry, placing it in the top 87.1%.
Is Orchid Pharma's FCF Margin % too high?
Orchid Pharma's current FCF Margin % is 0.00%. Based on the distribution chart, Orchid Pharma ranks #834 out of 958 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orchid Pharma has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Orchid Pharma ranks #834 out of 958 companies for FCF Margin %. This places Orchid Pharma in the lower half of its industry. The industry median FCF Margin % is 2.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.45, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Orchid Pharma and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current FCF Margin % of 0.00%. The stock's GF Value™ is $4.72, compared to a current price of $5.45 — trading 15.5% above its estimated fair value. The current FCF Margin % is 0.00%. Orchid Pharma's overall GF Score™ is 57/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 15.5% above its estimated GF Value™ of $4.72.
Key valuation signals for LUX:ORCHP:
FCF Margin %: 0.00%
GF Value™: $4.72 vs. price of $5.45 (15.5% above fair value)
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
57GF Score
Get the complete analysis for LUX:ORCHP
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 
